Longitude Capital

Investor type Venture Capital
Founders David Hirsch Marc Galletti Patrick Enright

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 92
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 66
Rounds per year 6.13
Lead investments 29
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 27
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

Longitude Capital appeared to be the VC, which was created in 2006. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Menlo Park.

Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Alphaeon, CardioDx, SutroVax. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Longitude Capital, startups are often financed by Kleiner Perkins, The Carlyle Group, TVM Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, OrbiMed, Kleiner Perkins. In the next rounds fund is usually obtained by RA Capital Management, Rock Springs Capital, Kleiner Perkins.

The current fund was established by Marc Galletti, Patrick Enright. We also calculated 7 valuable employees in our database.

The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Longitude Capital works on 1 percentage points less the average amount of lead investments. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. When the investment is from Longitude Capital the average startup value is 500 millions - 1 billion dollars. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Longitude Capital:
Typical Co-investors
Longitude Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Longitude Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
a16z Cultural Leadership Fund -
BorgWarner Auburn Hills, Michigan, United States
Costanoa Ventures California, Palo Alto, United States
Davidson Capital Group Florida, Santa Rosa Beach, United States
Dongguan Xiangwei Chuangye Touzi Hehuo Qiye China, Dongguang, Guangdong
Excubator Bangalore, India, Karnataka
Global Alliance for Genomics & Health Canada, Ontario, Toronto
GoldPoint Partners New York, New York, United States
Katalysator AS Norway, Oslo
Mauritius Investments Mauritius, Port Louis, Port Louis
Midea Group China, Guangdong Province, Huizhou
Prime Value Capital Management Beijing, Beijing, China
Santai Holding Chengdu, China, Sichuan
Shenzhen Jiacaili Zican China, Guangdong, Shenzhen
Stena Sessan Stockholm, Stockholm County, Sweden
Toyo Tsushin Kogyo Japan, Yamanashi, Yamanashi Prefecture
Westwood Ventures New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Quanta Therapeutics

Biotechnology
Health Care
Medical Device
Therapeutics
$60M26 Oct 2021 San Francisco, California, United States

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$100M09 Sep 2021 New York, New York, United States

Sydnexis

Manufacturing
Pharmaceutical
$45M10 Aug 2021 California, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$35M20 Jul 2021 Charlottesville, Virginia, United States

Cortica

Health Care
Hospital
Therapeutics
$60M29 Jun 2021 San Diego, California, United States

Ceribell

Biotechnology
Health Care
Health Diagnostics
Medical Device
$53M29 Apr 2021 Mountain View, California, United States

Alpha9 Theranostics

Biotechnology
Medical
Product Research
$8M28 Apr 2021 Vancouver, British Columbia, Canada

Cohere Health

Consumer Software
Health Care
SaaS
Software
$36M13 Apr 2021 Boston, Massachusetts, United States

Vera Therapeutics

Biotechnology
Health Care
$80M19 Jan 2021 South San Francisco, California, United States
News
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Cortica Raises $60M in Series C Funding

– Cortica from San Diego CA is focused on clinical services for autism and other neurodevelopmental conditions.
– Series C $60m funding round was led by Longitude Capital with participation from 406 Ventures, Adam Boehler, Questa Capital and Aperture Venture Partners and Silicon Valley Bank.
– The new financing will be used to accelerate growth, expand centers across multiple states, and investigate novel drug, device, and diagnostic technologies through sponsored and NIH-funded research.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Longitude Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: